American Association for Cancer Research

Table 2

Antitumor activity and toxicity of different schedules of topotecan administered intravenously in mice

Schedule of administration^a	Life span (days)	Increased life span (%)	Maximum body weight loss (%)
Controls	59 ± 2.1
12.5 mg/kg × 1	60.1 ± 14.6	0	1
2.5 mg/kg (d × 5)^b	82.3 ± 3.4	40	7.3
1.25 mg/kg (d × 5)2^b	77.8 ± 8	32	2.4
0.625 mg/kg (d × 5)4^b	96 ± 6	63	0

Schedule of administration^a	Life span (days)	Increased life span (%)	Maximum body weight loss (%)
Controls	59 ± 2.1
12.5 mg/kg × 1	60.1 ± 14.6	0	1
2.5 mg/kg (d × 5)^b	82.3 ± 3.4	40	7.3
1.25 mg/kg (d × 5)2^b	77.8 ± 8	32	2.4
0.625 mg/kg (d × 5)4^b	96 ± 6	63	0

Topotecan treatment began 3 days after tumor implantation.

Topotecan was administered i.v. 5 days/week, for 1, 2, or 4 consecutive weeks.